

AI
Conclude
for Modulation of Triglyceride Levels and Treatment of Dyslipidemia," filed January 10, 2000, the contents of which are hereby incorporated by reference in their entireties.

REMARKS

In accordance with 37 C.F.R. § 1.121, a marked up copy of the presently amended paragraph of the specification is appended hereto. Deletions to the originally filed text are noted by bracketing. Additions are noted by underlining.

The Commissioner is hereby authorized to charge any fees for this submission that may be incurred or credit any overpayment of fees to Deposit Account No. 50-1273. The Examiner is invited to contact Applicants' undersigned Representative if it is believed that prosecution may be furthered hereby.

Respectfully submitted,

Kolterman et al.

Dated: _____

10-24-01

By: _____

Lisa M. McGeehan

Lisa M. McGeehan
Reg. No. 41,185

LMM:bjk

BROBECK, PHLEGER & HARRISON LLP
12390 El Camino Real
San Diego, CA 92130-2081
Telephone: (858) 720-2500
Facsimile: (858) 720-2555



MARKED UP VERSION OF AMENDED PORTIONS OF THE SPECIFICATION

This application claims priority from U.S. Provisional Application 60/116,380, entitled "Novel Exendin Agonist Formulations and Methods of Administration Thereof," filed January 14, 1999 (and the corresponding PCT application filed January 14, 2000, Serial No. PCT/US00/00902 [[not yet assigned]], U.S. Provisional Application 60/132,017, entitled "Methods for Glucagon Suppression," filed April 30, 1999, and U.S. Provisional Application [60/[not yet assigned]] 60/175,365, entitled "Use of Exendins and Agonists Thereof for Modulation of Triglyceride Levels and Treatment of Dyslipidemia," filed January 10, 2000, the contents of which are hereby incorporated by reference in their entirety.